These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33526303)

  • 21. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
    Karelkina EV; Goncharova NS; Simakova MA; Moiseeva OM
    Kardiologiia; 2020 Mar; 60(4):36-42. PubMed ID: 32394855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
    Simonneau G; Torbicki A; Hoeper MM; Delcroix M; Karlócai K; Galiè N; Degano B; Bonderman D; Kurzyna M; Efficace M; Giorgino R; Lang IM
    Eur Respir J; 2012 Oct; 40(4):874-80. PubMed ID: 22362844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
    Sardana M; Moll M; Farber HW
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience of selexipag titration in pulmonary arterial hypertension.
    Cullivan S; Natarajan A; Boyle N; McCormack C; Gaine S; McCullagh B
    Br J Cardiol; 2021; 28(3):32. PubMed ID: 35747707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
    Howard LS; Rosenkranz S; Frantz RP; Hemnes AR; Pfister T; Hsu Schmitz SF; Skåra H; Humbert M; Preston IR
    Chest; 2023 Feb; 163(2):407-418. PubMed ID: 36089068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
    Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
    Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N
    Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selexipag for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang IM
    Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
    Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.